The fiscal 2015 funding bill for the FDA that's now headed to the House floor has become a bully pulpit to keep the agency from backsliding on commitments ranging from accelerated approval and abuse deterrence to science-based, data-driven decision-making. Read More
Rodin Therapeutics Inc., a company co-founded by Proteros Biostructures GmbH and Atlas Venture, raised $12.9 million in a series A round to take forward two sets of epigenetic modulators that are in development for Alzheimer's disease. Read More
SHANGHAI – Hutchison Medipharma Ltd. (HMP) is set to turn a corner announcing strong early results for not one, but three of its oncology drugs at ASCO 2014 this weekend in Chicago. Arguably the most exciting is the phase I data for Volitinib, a c-Met inhibitor that has shown strong results in patients with papillary renal cell carcinoma (PRCC), a rare form of cancer with no existing treatment. Read More
SEOUL, South Korea – With one eye firmly planted on future economic growth, South Korea is taking steps to boost its biotechnology industry by putting resources into a wide range of traditional and emerging subsectors from biosimilars to stem cell treatments. Read More
LONDON – The discovery of a compound that can prevent replication of various coronaviruses – which cause common respiratory infections as well as rare but highly dangerous infections – has raised hopes that it may be possible in the future to develop drugs to treat these infections. Read More
Biomedical competitors, fierce as ever, are finding complementary aid in mission-driven collaborations, according to a new survey of the largely unmapped consortia landscape. Consortia-pedia, a new project of the nonprofit Fastercures, is documenting more than a decade of progress in the fast-growing space. Read More
Advaxis Inc., of Princeton, and Inventiv Health Clinical, a clinical research organization, said they entered a master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis' pipeline. Read More
Boston Therapeutics Inc., of Manchester, N.H., began a five-week, randomized, double-blind phase IIb study to assess the efficacy and safety of Sugardown, its marketed dietary supplement, in 24 patients with type 2 diabetes taking metformin. Read More
Biocryst Pharmaceuticals Inc., of Research Triangle Park, N.C., plans to raise $100 million through a public offering of 10 million shares priced at $10 each. Read More
Nuvo Research Inc., of Mississauga, Ontario, said a third party received FDA approval to market and sell a topical diclofenac sodium 1.5 percent solution in the U.S. Read More
Eisai Ltd., of Hatfield, UK, part of Eisai Co. Ltd., said data from a large extension study of Fycompa (perampanel), published online in Epilepsia, showed the epilepsy treatment reduced seizure frequency over sustained periods of up to two years of treatment. Read More
